Understanding why Adderall can become addictive helps clinicians develop better treatments, prevention strategies, and interventions for stimulant misuse
What makes GLP-1s particularly sophisticated is their glucose-dependent action they only stimulate insulin when blood sugar levels are elevated, minimizing hypoglycemia risk
Beyond Diabetes and Obesity: Researchers are studying numerous additional indications that could expand the use of these medications beyond diabetes and obesity
Most individuals start to see results within a few weeks of beginning peptide therapy
Alfthan G, Aro A, and Gey KF (1997)
Oral Non-Peptide GLP-1 Receptor Agonists Market Key Players Analysis - Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Roche Holding AG